Is FRMM or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Neuphoria Therapeutics N/A -76.93% -54.76%

Does the media prefer FRMM or NEUP?

In the previous week, Forum Markets and Forum Markets both had 1 articles in the media. Forum Markets' average media sentiment score of 0.34 beat Neuphoria Therapeutics' score of 0.00 indicating that Forum Markets is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NEUP or CPHI?

Neuphoria Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 435.03%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor NEUP or CPHI?

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 1 articles in the media. Neuphoria Therapeutics' average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GANX or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Neuphoria Therapeutics N/A -76.93% -54.76%

Does the media prefer GANX or NEUP?

In the previous week, Gain Therapeutics and Gain Therapeutics both had 1 articles in the media. Gain Therapeutics' average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NEUP or THAR?

Neuphoria Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 435.03%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Neuphoria Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NEUP or THAR more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Tharimmune N/A -588.45% -264.41%

Does the media favor NEUP or ATRA?

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 1 articles in the media. Atara Biotherapeutics' average media sentiment score of 0.84 beat Neuphoria Therapeutics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neuphoria Therapeutics (NEUP) Competitors

$3.92 -0.01 (-0.13%)

As of 02:33 PM Eastern

Compare

NEUP vs. FRMM, CPHI, GANX, THAR, and ATRA

Should you buy Neuphoria Therapeutics stock or one of its competitors? MarketBeat compares Neuphoria Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neuphoria Therapeutics include Forum Markets (FRMM), China Pharma (CPHI), Gain Therapeutics (GANX), Tharimmune (THAR), and Atara Biotherapeutics (ATRA).

How does Neuphoria Therapeutics compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and Neuphoria Therapeutics (NASDAQ:NEUP) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

4.1% of Forum Markets shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 25.2% of Forum Markets shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Forum Markets and Forum Markets both had 1 articles in the media. Forum Markets' average media sentiment score of 0.34 beat Neuphoria Therapeutics' score of 0.00 indicating that Forum Markets is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neuphoria Therapeutics' return on equity of -76.93% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Neuphoria Therapeutics has higher revenue and earnings than Forum Markets. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	11.52	-$450.52M	-$36.07	N/A
Neuphoria Therapeutics	$15.65M	1.35	-$370K	-$11.06	N/A

Forum Markets currently has a consensus price target of $10.00, indicating a potential upside of 77.43%. Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 435.03%. Given Neuphoria Therapeutics' higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Forum Markets has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Summary

Forum Markets and Neuphoria Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to China Pharma?

Neuphoria Therapeutics (NASDAQ:NEUP) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Neuphoria Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
China Pharma	-85.56%	-63.93%	-31.42%

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 6.4% of China Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Neuphoria Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Neuphoria Therapeutics has higher revenue and earnings than China Pharma. China Pharma is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.35	-$370K	-$11.06	N/A
China Pharma	$3.99M	11.83	-$3.08M	-$0.55	N/A

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 1 articles in the media. Neuphoria Therapeutics' average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neuphoria Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 435.03%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Neuphoria Therapeutics beats China Pharma on 8 of the 14 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Neuphoria Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,501.28	-$20.16M	-$0.58	N/A
Neuphoria Therapeutics	$15.65M	1.35	-$370K	-$11.06	N/A

Neuphoria Therapeutics' return on equity of -76.93% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gain Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Gain Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 326.14%. Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 435.03%. Given Neuphoria Therapeutics' higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Gain Therapeutics and Gain Therapeutics both had 1 articles in the media. Gain Therapeutics' average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Neuphoria Therapeutics beats Gain Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Tharimmune?

Neuphoria Therapeutics (NASDAQ:NEUP) and Tharimmune (NASDAQ:THAR) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neuphoria Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for Neuphoria Therapeutics and 0 mentions for Tharimmune. Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Tharimmune	Neutral

Neuphoria Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 435.03%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Neuphoria Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Neuphoria Therapeutics has higher revenue and earnings than Tharimmune. Tharimmune is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.35	-$370K	-$11.06	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Neuphoria Therapeutics' return on equity of -76.93% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Tharimmune	N/A	-588.45%	-264.41%

Summary

Neuphoria Therapeutics beats Tharimmune on 10 of the 13 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Atara Biotherapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 1 articles in the media. Atara Biotherapeutics' average media sentiment score of 0.84 beat Neuphoria Therapeutics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Neuphoria Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 435.03%. Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential upside of 7.47%. Given Neuphoria Therapeutics' higher probable upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atara Biotherapeutics has higher revenue and earnings than Neuphoria Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.35	-$370K	-$11.06	N/A
Atara Biotherapeutics	$23.14M	3.44	$32.69M	-$0.67	N/A

Neuphoria Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market.

Neuphoria Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Neuphoria Therapeutics' return on equity of -76.93% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Summary

Atara Biotherapeutics beats Neuphoria Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Neuphoria Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEUP vs. The Competition

Export

Metric	Neuphoria Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.21M	$3.54B	$6.80B	$13.01B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.36	7.36	279.98	25.51
Price / Sales	1.35	1,272.68	649.35	116.02
Price / Cash	24.90	44.80	28.64	34.82
Price / Book	0.39	17.18	11.15	6.35
Net Income	-$370K	-$12.52M	$3.48B	$347.60M
7 Day Performance	3.02%	2.48%	2.51%	3.14%
1 Month Performance	16.12%	-5.41%	-2.78%	-2.08%
1 Year Performance	-49.55%	51.14%	64.32%	21.27%

Neuphoria Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEUP Neuphoria Therapeutics	2.2472 of 5 stars	$3.93 -0.1%	$21.00 +435.0%	-51.2%	$21.21M	$15.65M	N/A	N/A
FRMM Forum Markets	3.5809 of 5 stars	$5.73 +1.1%	$10.00 +74.5%	N/A	$76.73M	$6.55M	N/A	7
CPHI China Pharma	N/A	$1.52 -17.8%	N/A	-30.5%	$74.97M	$3.99M	N/A	250
GANX Gain Therapeutics	1.9733 of 5 stars	$1.75 -3.8%	$7.50 +328.6%	+21.5%	$74.64M	$50K	N/A	20	News Coverage Positive News Upcoming Earnings
THAR Tharimmune	N/A	$1.94 -5.8%	N/A	+55.6%	$73.20M	N/A	N/A	2	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEUP) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuphoria Therapeutics (NEUP) Competitors

NEUP vs. FRMM, CPHI, GANX, THAR, and ATRA

How does Neuphoria Therapeutics compare to Forum Markets?

Summary

How does Neuphoria Therapeutics compare to China Pharma?

Summary

How does Neuphoria Therapeutics compare to Gain Therapeutics?

Summary

How does Neuphoria Therapeutics compare to Tharimmune?

Summary

How does Neuphoria Therapeutics compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP vs. The Competition

Neuphoria Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuphoria Therapeutics (NEUP) Competitors

NEUP vs. FRMM, CPHI, GANX, THAR, and ATRA

How does Neuphoria Therapeutics compare to Forum Markets?

Do insiders & institutionals hold more shares of FRMM or NEUP?

Does the media prefer FRMM or NEUP?

Is FRMM or NEUP more profitable?

Which has preferable valuation and earnings, FRMM or NEUP?

Do analysts prefer FRMM or NEUP?

Which has more volatility and risk, FRMM or NEUP?

Summary

How does Neuphoria Therapeutics compare to China Pharma?

Is NEUP or CPHI more profitable?

Do insiders and institutionals hold more shares of NEUP or CPHI?

Which has more volatility & risk, NEUP or CPHI?

Which has preferable earnings & valuation, NEUP or CPHI?

Does the media favor NEUP or CPHI?

Do analysts prefer NEUP or CPHI?

Summary

How does Neuphoria Therapeutics compare to Gain Therapeutics?

Which has higher earnings & valuation, GANX or NEUP?

Is GANX or NEUP more profitable?

Do insiders & institutionals hold more shares of GANX or NEUP?

Which has more volatility & risk, GANX or NEUP?

Do analysts recommend GANX or NEUP?

Does the media prefer GANX or NEUP?

Summary

How does Neuphoria Therapeutics compare to Tharimmune?

Do insiders and institutionals have more ownership in NEUP or THAR?

Which has more risk and volatility, NEUP or THAR?

Does the media prefer NEUP or THAR?

Do analysts recommend NEUP or THAR?

Which has higher earnings and valuation, NEUP or THAR?

Is NEUP or THAR more profitable?

Summary

How does Neuphoria Therapeutics compare to Atara Biotherapeutics?

Does the media favor NEUP or ATRA?

Do insiders & institutionals believe in NEUP or ATRA?

Do analysts rate NEUP or ATRA?

Which has stronger earnings & valuation, NEUP or ATRA?

Which has more risk and volatility, NEUP or ATRA?

Is NEUP or ATRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP vs. The Competition

Neuphoria Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools